This subgroup analysis of the phase III APEX (Assessment of Proteasome Inhibition for Extending Remissions) trial examined whether prior exposure to specific therapies affected the relative efficacy of bortezomib versus dexamethasone in relapsed/refractory myeloma. Time to progression and overall survival were superior with bortezomib in all subgroups, with no evidence of interaction between any prior therapies and assignment to study therapy. Patients with prior thalidomide exposure had worse outcomes overall, but neither prior thalidomide nor prior autologous stem cell transplantation affected the relative efficacy of bortezomib versus dexamethasone. These results confirm the superiority of bortezomib over dexamethasone, regardless of prior exposure to specific therapies (clinicaltrials.gov: NCT00048230).

Additional Metadata
Keywords Bortezomib, Multiple myeloma, Sequence, Stem cell transplantation, Thalidomide
Persistent URL dx.doi.org/10.1111/j.1365-2141.2009.07875.x, hdl.handle.net/1765/24757
Citation
Vogl, D.T, Stadtmauer, E.A, Richardson, P.G, Sonneveld, P, Schuster, M.W, Irwin, D, … Anderson, K.C. (2009). Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. British Journal of Haematology, 147(4), 531–534. doi:10.1111/j.1365-2141.2009.07875.x